
Sign up to save your podcasts
Or


Several Texas bar owners have filed a lawsuit against Gov. Greg Abbot over his order to shut down bars for a second time since the pandemic began. Bar owners feel like they are being unfairly targeted when restaurants that serve alcohol can remain open and other businesses can continue to operate. Bars are especially vulnerable because people tend to gather in close quarters for extended periods of time, there is poor air ventilation, and virus particles can spread with people speaking loudly. Sarah Blaskovich, reporter at the Dallas Morning News, joins us for more.
Next, Moderna is currently the front-runner in developing a coronavirus vaccine. They will be entering the third phase of clinical trials this month with about 30,000 people participating. While there is a lot of hope riding on Moderna to come through, the company has no track record in developing an approved drug and is also using an unproven approach to making the vaccine. Still, the company is worth $24 billion because of its current work. Peter Loftus, reporter at the WSJ, joins us for more on vaccine front-runner, Moderna.
Learn more about your ad-choices at https://www.iheartpodcastnetwork.com
See omnystudio.com/listener for privacy information.
By iHeartPodcasts4
7777 ratings
Several Texas bar owners have filed a lawsuit against Gov. Greg Abbot over his order to shut down bars for a second time since the pandemic began. Bar owners feel like they are being unfairly targeted when restaurants that serve alcohol can remain open and other businesses can continue to operate. Bars are especially vulnerable because people tend to gather in close quarters for extended periods of time, there is poor air ventilation, and virus particles can spread with people speaking loudly. Sarah Blaskovich, reporter at the Dallas Morning News, joins us for more.
Next, Moderna is currently the front-runner in developing a coronavirus vaccine. They will be entering the third phase of clinical trials this month with about 30,000 people participating. While there is a lot of hope riding on Moderna to come through, the company has no track record in developing an approved drug and is also using an unproven approach to making the vaccine. Still, the company is worth $24 billion because of its current work. Peter Loftus, reporter at the WSJ, joins us for more on vaccine front-runner, Moderna.
Learn more about your ad-choices at https://www.iheartpodcastnetwork.com
See omnystudio.com/listener for privacy information.

4,677 Listeners

244 Listeners

8 Listeners

9 Listeners

351 Listeners

63 Listeners

250 Listeners

142 Listeners

237 Listeners

1,551 Listeners

840 Listeners

63 Listeners

277 Listeners

159 Listeners

1,045 Listeners

18 Listeners

193 Listeners

60 Listeners

34 Listeners

34 Listeners